METHOD
Method for quantitative assessment of protective immunity against SARS-CoV-2, its duration and antibody dynamics
1 Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia
2 Military Academy of Radiation, Chemical and Biological Defense, Kostroma, Russa
Correspondence should be addressed: Alexandr M. Karmishin
Shchukinskaya, 5/6, Moscow, 123182; ur.zmpsc@nihsimraka
Author contribution: All authors equally contributed to the methodology of the study, data acquisition, analysis and interpretation. All author participated in drafting the manuscript and editing its final version.
The level and duration of protective immunity are often analyzed qualitatively or semi-quantitatively. The same strategy is applied to the analysis of antibody dynamics. At some point in time t after exposure or immunization, the presence of immunity against the infection is inferred from the level of specific antibodies by comparing it to a reference value. This approach does not account for the stochastic nature of human disease after exposure to a pathogen. At the same time, it is not fully clear what antibody level should be considered protective. The aim of this study was to develop a mathematical model for quantitative determination of protective immunity against SARS-CoV-2 and its duration. We demonstrate that the problem of describing protective immunity in quantitative terms can be broken down into 2 interrelated problems: describing the quantitative characteristics of a pathogen’s virulence (in our case, the pathogen is SARS-CoV-2) and describing the dynamics of antibody titers in a biological organism. Below, we provide solutions for these problems and identify parameters of the model which describes such dynamics. Using the proposed model, we offer a theoretical solution to the problem of protective immunity and its duration. We also note that in order to quantitatively determine the studied parameters in a homogenous population group, it is necessary to know 5 parameters of the bivariate probability density function for correlated continuous random variables: the infective dose of the pathogen and the antibody titer at which the disease develops and which are still unknown.
Keywords: COVID-19, SARS-CoV-2, infective dose, probability of disease, antibody titer, protective immunity, immunity duration